1,340 reports of this reaction
2.7% of all CANAGLIFLOZIN reports
#6 most reported adverse reaction
WEIGHT DECREASED is the #6 most commonly reported adverse reaction for CANAGLIFLOZIN, manufactured by Janssen Pharmaceuticals, Inc.. There are 1,340 FDA adverse event reports linking CANAGLIFLOZIN to WEIGHT DECREASED. This represents approximately 2.7% of all 49,711 adverse event reports for this drug.
Patients taking CANAGLIFLOZIN who experience weight decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
WEIGHT DECREASED is a less commonly reported adverse event for CANAGLIFLOZIN, but still significant enough to appear in the safety profile.
In addition to weight decreased, the following adverse reactions have been reported for CANAGLIFLOZIN:
The following drugs have also been linked to weight decreased in FDA adverse event reports:
WEIGHT DECREASED has been reported as an adverse event in 1,340 FDA reports for CANAGLIFLOZIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
WEIGHT DECREASED accounts for approximately 2.7% of all adverse event reports for CANAGLIFLOZIN, making it a notable side effect.
If you experience weight decreased while taking CANAGLIFLOZIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.